Home / Health / Lecanemab: Hope and Safety for Early Alzheimer's
Lecanemab: Hope and Safety for Early Alzheimer's
11 Aug
Summary
- Lecanemab is proving safe and effective in real-world Alzheimer's treatment.
- Approximately 80% of patients remain on the drug for over a year.
- Most side effects resolve over time without hospitalization.
A recent study involving hundreds of patients indicates that the Alzheimer's drug lecanemab is as safe and effective in real-world settings as it was in clinical trials that led to its July 2023 approval.
Researchers tracked 230 patients with early Alzheimer's or mild memory impairment between 2023 and 2025. The findings reveal that nearly 80% of patients continued treatment for over a year, with most side effects resolving without additional medication or hospitalization.
Approximately 24% of patients experienced Amyloid Related Imaging Abnormalities (ARIA), such as brain swelling or bleeding, with carriers of the APOE4 gene being more susceptible. However, the study highlighted the need for better prediction tools for ARIA.
While lecanemab does not cure Alzheimer's, it can slow disease progression, offering patients valuable time. Researchers emphasize careful risk-benefit assessments to maximize these gains.
